Dr Ian Giles

Dr Ian GilesTel: 020 3447 9035
Fax: 020 3447 9278
Email: uclh.rheumatology@nhs.net

University College Hospital


Professional background

Ian Giles qualified from the Royal London Hospital in 1992 and carried out his general medical and rheumatology clinical training in various London hospitals. He completed his PhD followed by a Clinical Scientist Fellowship at University College London (both funded by Arthritis Research UK) and was appointed as Senior Lecturer and Honorary consultant rheumatologist at UCLH in 2007. In his clinical practice he sees both general rheumatology patients and helps to run the weekly autoimmune rheumatic disease clinic managing patients with a variety of diseases including systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). In addittion he has developed a specialist rheumatology-obstetric clinic to improve the care of these patients with rheumatic disease both before, during and immediately post-partum.

Research interests

  • Systemic lupus erythematosus
  • Antiphospholipid syndrome
  • Obstetric outcomes in patients with rheumatic disease


1. Mulla M., Brosens J., Chamley L.W., Giles I., Pericleous C., Rahman A., Joyce S.K., Panda B., Paidas M.J., Abrahams V.M. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. American Journal of Reproductive Immunology 2009;62:96-111.

2. Pericleous C., Rahman A and Giles I. Do antiphospholipid antibodies have direct pathologic effects upon endometrial and trophoblast cells? Current Rheumatology Reviews 2009;5:83-97.

3.  Giles I. and Rahman A. How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. Best Practice and Research Clinical Rheumatology 2009;23:525-37.

4.  Narshi C.B., Haider S., Ford C.F., Isenberg D.A. and Giles I.P. Rituximab as Early Therapy for Pulmonary Haemorrhage in Systemic Lupus Erythematosus. Rheumatology, 2009; doi: 10.1093/rheumatology/kep356

5.  Chen P and Giles I. Antibodies to Serine Proteases in the Antiphospholipid Syndrome. Current Rheumatology Reports, 2010;12:45-52.

6.  O’Neill S., Giles I., Lambrianides A., Manson J., D’Cruz  D., Schrieber L., March L., Latchman D., Isenberg D. and Rahman A. Antibodies to Apolipoprotein A1, High Density Lipoprotein and C-Reactive Protein are Associated with Disease Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatism, 2010;62:845-54.

7. Moody M.A., Liao H.X., Alam S.M., Scearce R.M., Plonk M.K., Kozink D.M., Drinker M.S., Xia S.M., Sutherland L.L., Tomaras G.D., Giles I.P., Kappes J.C., Ochsenbauer-Jambor C., Edmonds T.G., Soares M., Barbero G., Forthal D.N., Landucci G., Chang C., King S.W., Kavlie A., Denny T.N., Hwang K.K., Chen P.P., Thorpe P.E., Montefiori D.C., and Haynes B.F. Anti-Phospholipid Human Monoclonal Antibodies Inhibit CCR5-Tropic HIV-1 and Induce β-Chemokines. Journal of Experimental Medicine, 2010;207:763-76.

8. Ioannou Y. and Giles I. New therapies for the management of the antiphospholipid syndrome. Current Medical Literature 2009;28:81-89.

9. Lambrianides A., Carroll C., Pierangeli SS., Pericleous C., Branch W., Rice J., Latchman DS., Townsend P., Isenberg D.A., Rahman A. and Giles IP. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signalling pathways. Journal of Immunology, 2010;184:6622-8.

10. Narshi C., Giles I. and Rahman A. The Endothelium: an interface between Autoimmunity and Atherosclerosis in Systemic Lupus Erythematosus? Lupus, in-press.

GMC/GDC number: 3588727